Institute of Molecular Oncology, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Clinic of Diagnostic and Interventional Radiology, Philipps-University, Core Facility 7T-small animal MRI, Marburg, Germany.
Mol Cancer. 2022 Oct 3;21(1):191. doi: 10.1186/s12943-022-01661-2.
In vivo gene editing of somatic cells with CRISPR nucleases has facilitated the generation of autochthonous mouse tumors, which are initiated by genetic alterations relevant to the human disease and progress along a natural timeline as in patients. However, the long and variable, orthotopic tumor growth in inner organs requires sophisticated, time-consuming and resource-intensive imaging for longitudinal disease monitoring and impedes the use of autochthonous tumor models for preclinical studies.
To facilitate a more widespread use, we have generated a reporter mouse that expresses a Cre-inducible luciferase from Gaussia princeps (GLuc), which is secreted by cells in an energy-consuming process and can be measured quantitatively in the blood as a marker for the viable tumor load. In addition, we have developed a flexible, complementary toolkit to rapidly assemble recombinant adenoviruses (AVs) for delivering Cre recombinase together with CRISPR nucleases targeting cancer driver genes.
We demonstrate that intratracheal infection of GLuc reporter mice with CRISPR-AVs efficiently induces lung tumors driven by mutations in the targeted cancer genes and simultaneously activates the GLuc transgene, resulting in GLuc secretion into the blood by the growing tumor. GLuc blood levels are easily and robustly quantified in small-volume blood samples with inexpensive equipment, enable tumor detection already several months before the humane study endpoint and precisely mirror the kinetics of tumor development specified by the inducing gene combination.
Our study establishes blood-based GLuc monitoring as an inexpensive, rapid, high-throughput and animal-friendly method to longitudinally monitor autochthonous tumor growth in preclinical studies.
利用 CRISPR 核酸酶对体细胞进行体内基因编辑,促进了自发肿瘤的产生,这些肿瘤由与人类疾病相关的遗传改变引发,并按照与患者相同的自然时间进程进展。然而,在内部器官中的长而多变的原位肿瘤生长需要复杂、耗时和资源密集型的成像技术来进行纵向疾病监测,这阻碍了自发肿瘤模型在临床前研究中的应用。
为了促进更广泛的应用,我们构建了一种报告小鼠,该小鼠表达来自 Gaussia princeps(GLuc)的 Cre 诱导型荧光素酶,该酶通过细胞的能量消耗过程分泌,可以作为有活力的肿瘤负荷的标志物在血液中进行定量测量。此外,我们开发了一种灵活的、互补的工具包,用于快速组装携带 Cre 重组酶的重组腺病毒(AVs),以及针对癌症驱动基因的 CRISPR 核酸酶。
我们证明,通过气管内感染 GLuc 报告小鼠的 CRISPR-AVs,可以有效地诱导靶向癌症基因突变驱动的肺癌肿瘤,并同时激活 GLuc 转基因,导致生长中的肿瘤将 GLuc 分泌到血液中。通过使用廉价设备从小体积血液样本中轻松且稳健地定量 GLuc 血液水平,可以在人类研究终点前数月检测到肿瘤,并精确反映由诱导基因组合指定的肿瘤发展动力学。
我们的研究确立了基于血液的 GLuc 监测作为一种廉价、快速、高通量且对动物友好的方法,用于在临床前研究中纵向监测自发肿瘤的生长。